Seagen Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1998-01-01
- Employees
- 3.2K
- Market Cap
- -
- Website
- http://www.seagen.com
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- Conditions
- Interventions
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 332
- Registration Number
- NCT04879329
- Locations
- 🇦🇺
GenesisCare North Shore (Oncology), St Leonards, Other, Australia
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 502
- Registration Number
- NCT04697628
- Locations
- 🇺🇸
Willis-Knighton Physician Network/Gynecologic Oncology Associates, Shreveport, Louisiana, United States
🇺🇸Maryland Oncology Hematology, P.A., Columbia, Maryland, United States
🇮🇹Fondazione Policlinico Universitario Agostino, Roma, Other, Italy
A Study of SGN-STNV in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT04665921
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸University of California, San Francisco | HDFCCC - Hematopoietic Malignancies, San Francisco, California, United States
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT04609566
- Locations
- 🇺🇸
Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸cCARE - Northern, Fresno, California, United States
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
- Conditions
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 217
- Registration Number
- NCT04579380
- Locations
- 🇺🇸
HealthPartners Institute, Saint Louis Park, Minnesota, United States
🇺🇸Texas Oncology, P.A. - Dallas, Dallas, Texas, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
- Conditions
- Interventions
- First Posted Date
- 2020-09-29
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT04569032
- Locations
- 🇺🇸
Stanford Cancer Center / Blood and Marrow Transplant Program, Stanford, California, United States
🇺🇸Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States
🇺🇸Johns Hopkins Medical Center, Washington, District of Columbia, United States
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT04539938
- Locations
- 🇺🇸
UCLA Department of Medicine - Hematology & Oncology, Los Angeles, California, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04499924
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04430738
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇯🇵National Cancer Center Hospital, Chuo-ku, Other, Japan
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
- Conditions
- Interventions
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT04404283
- Locations
- 🇺🇸
Central Alabama Research, Birmingham, Alabama, United States
🇺🇸Alabama Oncology, Birmingham, Alabama, United States
🇺🇸Arizona Oncology Associates, PC - NAHOA, Goodyear, Arizona, United States